Literature DB >> 19269310

Tumor-associated macrophages: effectors of angiogenesis and tumor progression.

Seth B Coffelt1, Russell Hughes, Claire E Lewis.   

Abstract

Tumor-associated macrophages (TAMs) are a prominent inflammatory cell population in many tumor types residing in both perivascular and avascular, hypoxic regions of these tissues. Analysis of TAMs in human tumor biopsies has shown that they express a variety of tumor-promoting factors and evidence from transgenic murine tumor models has provided unequivocal evidence for the importance of these cells in driving angiogenesis, lymphangiogenesis, immunosuppression, and metastasis. This review will summarize the mechanisms by which monocytes are recruited into tumors, their myriad, tumor-promoting functions within tumors, and the influence of the tumor microenvironment in driving these activities. We also discuss recent attempts to both target/destroy TAMs and exploit them as delivery vehicles for anti-cancer gene therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19269310     DOI: 10.1016/j.bbcan.2009.02.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  141 in total

Review 1.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

2.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

3.  Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Authors:  Elena Gallego; Luis Vicioso; Martina Alvarez; Isabel Hierro; Lidia Pérez-Villa; Alfredo Blanes; Alfredo Matilla
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

Review 4.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

Review 5.  Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function.

Authors:  Helge Wiig; Doruk Keskin; Raghu Kalluri
Journal:  Matrix Biol       Date:  2010-08-18       Impact factor: 11.583

Review 6.  Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.

Authors:  Bruce A Corliss; Mohammad S Azimi; Jennifer M Munson; Shayn M Peirce; Walter L Murfee
Journal:  Microcirculation       Date:  2016-02       Impact factor: 2.628

7.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

8.  Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling.

Authors:  R Srinivasan; E Ozhegov; Y W van den Berg; B J Aronow; R S Franco; M B Palascak; J T Fallon; W Ruf; H H Versteeg; V Y Bogdanov
Journal:  J Thromb Haemost       Date:  2011-10       Impact factor: 5.824

9.  Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development.

Authors:  Yuchen Liu; Luming Zhao; Dameng Li; Yuan Yin; Chen-Yu Zhang; Jing Li; Yujing Zhang
Journal:  Protein Cell       Date:  2013-11-07       Impact factor: 14.870

10.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.